Accordant Advisory Group’s Altimmune ALT Stock Holding History

Accordant Advisory Group’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$3.87K	–	163
2025 Q2	$3.87K	Buy	+1,000	New	+$5.41K	﹤0.01%	146

Other funds holding ALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Accordant Advisory Group's ALT Position: Q3 2025 in Review

Accordant Advisory Group sold out of Altimmune (ALT) in Q3 2025, closing a stake of 1,000 shares — an estimated $3.87K sold.

Accordant Advisory Group first reported a position in ALT in Q2 2025 and held it in 1 quarter. The position peaked at $3.87K in Q2 2025. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

Accordant Advisory Group reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
Accordant Advisory Group sold 1,000 Altimmune shares in Q3 2025, an estimated $3.87K.
Accordant Advisory Group first reported a position in Altimmune in Q2 2025 and held it in 1 quarter.
Accordant Advisory Group's Altimmune position peaked at $3.87K in Q2 2025.
158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Accordant Advisory Group's 13F filing for Q3 2025, filed 22 Oct 2025.